Cythemias
Conference Coverage
Ruxolitinib improves disease control in PV
©ASCO/Phil McCarten CHICAGO—The JAK1/2 inhibitor ruxolitinib may be a “valuable new treatment option” for patients with polycythemia vera (PV)...
Conference Coverage
Studies confirm importance of CALR mutation in PMF
One study showed that PMF patients with mutated CALR had prolonged overall survival (OS) compared to patients with wild-type CALR.
News
FDA removes partial clinical hold on imetelstat
The partial hold was placed because of a safety signal of liver toxicity in myelofibrosis patients receiving the drug. The principal investigator...
News
Mutations implicated in hematologic disorders
Credit: Jeremy L.
News
New insight into TPO and platelet production
Credit: Walter and Eliza Hall Institute of Medical Research Investigators say they’ve determined how thrombopoietin (TPO) stimulates platelet...
News
FDA places imetelstat trials on hold
The hold temporarily suspends all ongoing clinical trials of imetelstat sponsored by the drug’s maker, Geron Corporation. It’s possible that...
News
Nanoparticle therapy active in B-cell malignancies
An experimental nanoparticle therapy has shown preclinical activity against a range of B-cell malignancies, researchers have reported. The...
News
Report reveals detailed data of ruxolitinib in MF
Ruxolitinib can ease the symptoms of myelofibrosis and improve patient survival, according to results of the COMFORT-I study. Detailed data from...
News
JAK inhibitor ruxolitinib improves treatment landscape in MF
CHICAGO—Two phase 3 studies demonstrate the effectiveness of the investigational Janus kinase (JAK) inhibitor INC424 (ruxolitinib) in treating...